By integrating mechanistic and predictive analyses, this study not only establishes a high-precision, interpretable model for IPF treatment response prediction but also positions CXCL14 as a novel therapeutic target by delineating its dual roles in fibrogenesis and immune dysregulation. This evidence concerns the gene CXCL14 and idiopathic pulmonary fibrosis.